GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms

被引:5
作者
Yang, Naery [1 ]
Park, Sholhui [1 ]
Cho, Min-Sun [2 ]
Lee, Miae [1 ]
Hong, Ki-Sook [1 ]
Mun, Yeung Chul [3 ]
Seong, Chu-Myong [3 ]
Huh, Hee Jin [4 ]
Huh, Jungwon [1 ]
机构
[1] Ewha Womans Univ, Coll Med, Dept Lab Med, 1071 Anyangcheon Ro, Seoul 07985, South Korea
[2] Ewha Womans Univ, Coll Med, Dept Pathol, Seoul, South Korea
[3] Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[4] Dongguk Univ Ilsan Hosp, Dept Lab Med, 27 Dongguk Ro, Goyang 10326, South Korea
基金
新加坡国家研究基金会;
关键词
Polycythemia vera; Essential thrombocythemia; Prefibrotic primary myelofibrosis; Primary myelofibrosis; GATA1; BONE-MARROW BIOPSY; ESSENTIAL THROMBOCYTHEMIA; ALLELE BURDEN; PRIMARY MYELOFIBROSIS; POLYCYTHEMIA-VERA; JAK2; V617F; DIAGNOSIS; MUTATIONS; IMPACT; MEGAKARYOCYTES;
D O I
10.3343/alm.2018.38.4.296
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: This study aimed to determine GATA1 expression levels to better characterize subgroups in BCR/ABL1-negative myeloproliferative neoplasms (MPNs). Methods: This study enrolled 49 patients diagnosed as having BCR/ABL1-negative MPN on the basis of the 2016 World Health Organization classification : nine polycythemia vera (PV), 17 essential thrombocythemia (ET), 12 prefibrotic primary myelofibrosis (prePMF), and 11 overt primary myelofibrosis (PMF). Relevant clinical and laboratory data were retrieved from the medical records. The molecular analysis of CALR and MPL mutations and quantification of JAK2 V617F allele burden were performed. GATA1 expression was assessed by an immunohistochemical assay on bone marrow biopsy. GATA1 expression was analyzed serially in 18 patients. Results: GATA1 expression decreased significantly in PMF compared with that in other subtypes, while no statistical difference was identified between ET and prePMF. GATA1 expression did not differ according to the mutation profiles or the allele burden of JAK2 V617F, but it decreased significantly in patients with overt fibrosis or leukemic transformation. Conclusions: Our results suggest that GATA1 expression is significantly low in PMF and decreases with progressive fibrosis and possibly with leukemic transformation, although our attempt to accurately distinguish between subgroups using GATA1 immunohistochemical approach did not achieve statistical significance. A large patient cohort with long term follow-up is required to evaluate the prognostic value of GATA1 expression.
引用
收藏
页码:296 / +
页数:12
相关论文
共 50 条
[31]   Clinical and Molecular Attributes of Patients With BCR/ABL1-negative MyeloproliferativeNeoplasms in India: Real-world Data and Challenges [J].
Singh, Suvir ;
Kaur, Komalpreet ;
Paul, Davinder ;
Jain, Kunal ;
Singh, Jagdeep ;
Narang, Vikram ;
Garg, Bhavna ;
Sood, Neena ;
Dhillon, Barjinderjit .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (06) :E569-E578
[32]   Distinctive Attributes of Indian Patients With Classical BCR::ABL1 Negative Myeloproliferative Neoplasms: Unified Clinical and Laboratory Data [J].
Singh, Suvir ;
Singh, Jagdeep ;
Mehta, Arpan ;
Sharma, Rintu ;
Joshi, Kaveri ;
Jain, Kunal ;
Paul, Davinder ;
Oberoi, Gurleen ;
Jindal, Nandita ;
Dhillon, Barjinderjit ;
Narang, Vikram .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (05) :360-369.e1
[33]   Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms [J].
Porto-Soares, Moyses Antonio ;
Oliveira, Rafael Daltro de ;
Cortopassi, Gabriel Macedo ;
Machado-Neto, Joao Agostinho ;
Palma, Leonardo Carvalho ;
Figueiredo-Pontes, Lorena Lobo de .
HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2020, 42 (03) :238-244
[34]   Recombinant Interferon Alfa in BCR/ ABL-Negative Chronic Myeloproliferative Neoplasms [J].
El Bitar, Sandy ;
Arcasoy, Murat O. .
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (02) :80-89
[35]   Increased mRNA expression for serotonin receptor 1B (HTR1B) is associated with thrombosis in BCR::ABL1-negative myeloproliferative neoplasms [J].
Gurban, Petruta ;
Mambet, Cristina ;
Botezatu, Anca ;
Necula, Laura G. ;
Matei, Lilia ;
Neagu, Ana Iulia ;
Pitica, Ioana Madalina ;
Dragu, Laura Denisa ;
Schulman, Alina Nastasie ;
Ataman, Marius ;
Nedeianu, Saviana ;
Chivu-Economescu, Mihaela ;
Bleotu, Coralia ;
Anton, Gabriela ;
Diaconu, Carmen Cristina .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (16)
[36]   Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms [J].
Guo, Xiaodong ;
Jia, Wenbo ;
Yang, Xinyu ;
Jia, Hexiao ;
Wu, Hanyang ;
Wei, Yihong ;
Can, Can ;
He, Na ;
Zhang, Hailei ;
Liu, Wancheng ;
Yu, Shuang ;
Ma, Daoxin .
TRANSLATIONAL ONCOLOGY, 2025, 58
[37]   Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms [J].
Ding, Li ;
Luo, Jie ;
Zhang, Jing ;
Wang, Ji ;
Li, Zhao ;
Huang, Juan ;
Chai, Li ;
Mu, Jiao ;
Zhao, Beibei ;
Zhong, Yi ;
Zhang, Lin ;
Liu, Lin .
ONCOLOGY LETTERS, 2022, 23 (01)
[38]   Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms [J].
Doehner, K. ;
Stegelmann, F. ;
Schlenk, R. F. ;
Griesshammer, M. .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (42) :2171-2178
[39]   Oxidant/Antioxidant Status in Patients with BCR-ABL1 Negative Myeloproliferative Neoplasms [J].
Benguella-Benmansour, Meriem ;
Boucherit, Kebir ;
Mesli, Naima .
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2025, 41 (01) :23-30
[40]   BCR-ABL1-Negative Chronic Myeloproliferative Neoplasms and Pulmonary Hypertension: A Prospective Long-Term Follow-up Study of the Impact of Pulmonary Hypertension on Survival [J].
Payzin, Kadriye Bahriye ;
Savasoglu, Kaan ;
Alacacioglu, Inci ;
Dalgic, Elif Ebru ;
Kucukzeybek, Betul Bolat ;
Calli, Aylin Orgen ;
Bener, Sadi ;
Payzin, Serdar .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (02) :125-131